Genialis, a leading therapeutic intelligence company, introduced Genialis™ BioBridge in San Diego. This innovative solution aims to assist pharmaceutical sponsors in converting clinical data from Chinese patients into biomarker-ready assets for trials and regulatory submissions in the West. This move responds to the evolving drug development scenario, where numerous groundbreaking oncology treatments are initially confirmed in China before progressing to North America and Europe for further development. The BioBridge platform is expected to facilitate this transition seamlessly.